E3 ubiquitin ligase Listerin regulates macrophage cholesterol efflux and atherosclerosis by targeting ABCA1
Journal of Clinical Investigation · 15.08.2025 · 135 (16)
DOI: 10.1172/jci186509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 17.06.2025. Verfasst von Lei Cao und 17 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese …. Hauptthemen laut MEDLINE: Atherosclerosis, ATP Binding Cassette Transporter 1, Cholesterol, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Atherosclerosis arises from disrupted cholesterol metabolism, notably impaired macrophage cholesterol efflux leading to foam cell formation. Through single-cell and bulk RNA-Seq, we identified Listerin E3 ubiquitin protein ligase 1 (Listerin) as a regulator of macrophage cholesterol metabolism. Listerin expression increased during atherosclerosis progression in humans and rodents. Its deficiency suppressed cholesterol efflux, promoted foam cell formation, and exacerbated plaque features (macrophage infiltration, lipid deposition, necrotic cores) in macrophage-specific KO mice. Conversely, Listerin overexpression attenuated these atherosclerotic manifestations. Mechanistically, Listerin stabilizes ABCA1, a key cholesterol efflux mediator, by catalyzing K63-linked polyubiquitination at residues K1884/K1957, countering ESCRT-mediated lysosomal degradation of ABCA1 induced by oxidized LDL (oxLDL). ABCA1 agonist erythrodiol restored cholesterol efflux in Listerin-deficient macrophages, while KO of ABCA1 abolished Listerin’s effects in Tsuchiya human monocytic leukemia line (THP-1) cells. This study establishes Listerin as a protective factor in atherosclerosis via posttranslational stabilization of ABCA1, offering a potential therapeutic strategy targeting ABCA1 ubiquitination to enhance cholesterol efflux.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Innovation and Transformation of Luobing Theory; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese…
- Organ Procurement Organizations, Qilu Hospital of Shandong University, Jinan, Shandong, China.
- Department of Cardiology, Zibo Central Hospital, Zibo, Shandong, China.
- Cardiovascular Disease Research Center, Jinan Central Hospital, Shandong First Medical University, Jinan, Shandong, China.
- Key Laboratory of Infection and Immunity of Shandong Province, Department of Immunology, Cheeloo College of Medicine, Shandong University, Jinan, China.
Zitieren
APA
Cao, L., Zhang, J., Yu, L., Yang, W., Qi, W., Ren, R., Liu, Y., Hou, Y., Cao, Y., Li, Q., Wang, X., Zhang, Z., Li, B., Sui, W., Zhang, Y., Gao, C., Zhang, C., & Zhang, M. (2025). E3 ubiquitin ligase Listerin regulates macrophage cholesterol efflux and atherosclerosis by targeting ABCA1. Journal of Clinical Investigation, 135(16). https://doi.org/10.1172/jci186509
Vancouver
Cao L, Zhang J, Yu L, Yang W, Qi W, Ren R, et al. E3 ubiquitin ligase Listerin regulates macrophage cholesterol efflux and atherosclerosis by targeting ABCA1. Journal of Clinical Investigation. 2025;135(16). doi:10.1172/jci186509
BibTeX
@article{Cao2025,
author = {Cao, Lei and Zhang, Jie and Yu, Liwen and Yang, Wei and Qi, Wenqian and Ren, Ruiqing and Liu, Yapeng and Hou, Yonghao and Cao, Yu and Li, Qian and Wang, Xiaohong and Zhang, Zhengguo and Li, Bo and Sui, Wenhai and Zhang, Yun and Gao, Chengjiang and Zhang, Cheng and Zhang, Meng},
title = {E3 ubiquitin ligase Listerin regulates macrophage cholesterol efflux and atherosclerosis by targeting ABCA1},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {16},
doi = {10.1172/jci186509}
}
EUVIMED